Walt Disney Co vs Eli Lilly And Co — how do they compare? Walt Disney Co trades at $97.54 (market cap $166.48B), while Eli Lilly And Co trades at $1,147 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 6.2× Walt Disney Co's market cap, and Walt Disney Co pays the higher dividend (1.56%). Which is the better fit depends on your goals.
| DIS | LLY | |
|---|---|---|
Market Cap | $166.48B | $1.03T |
Volume | 7,546,013 | — |
Sector | Media | Health |
52-Week High | $122.94 | $1.24K |
52-Week Low | $92.40 | $625.65 |
Enterprise Value | $208.16B | $1.07T |
Dividend Yield | 1.56% | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $96.01, up 0.4% today, with a bearish technical signal but strong fundamentals including three consecutive quarterly EPS beats. Revenue grew to $94.43B in 2025 with net income surging to $12.40B. The stock shows a P/E of 15.34 and P/S of 1.77, trading below the consensus price target of $125.60. Recent news highlights advertising opportunities from major events like the Super Bowl, though box office performance for new Star Wars film raises concerns.
Outlook remains positive with analyst consensus at Buy (61.9%) and a 31% upside to target, driven by earnings momentum and theme park investments. Risks include regulatory disputes with the FCC, streaming competition, and film profitability. Cash flow trends show operational strength but negative net flows from high investing activity.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →